January 30, 2020 Amarantus Acquires Majority Inter
Post# of 30028
(Total Views: 620)
Posted On: 01/30/2020 10:09:42 AM
January 30, 2020
Amarantus Acquires Majority Interest in CBD
Wellness Company Hempori
Strong customer retention at both stores in Dallas, TX with growing online presence
Focus on delivering wellness solutions by engaging customers to participate in clinical studies and provide
outcomes data to determine utility of branded CBD products
Order placed for hemp smokes to begin tobacco smoking cessation program
New York, NY and Dallas, TX , Jan. 30, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus
Bioscience Holdings, Inc. (OTC Pink: AMBS) (“Amarantus,” or AMBS), a biotechnology holding company pursuing
proprietary therapeutics and diagnostics through its subsidiaries, today announced that it has acquired a controlling
interest in Hempori, Inc., a CBD wellness retailer in Dallas, TXwith 2 stores and a growing physical and online
presence. Concurrent with this announcement, Hempori has placed an initial purchase order for hemp smokes from
Emerald Organic Products, Inc. (OTCPK: EMOR), an Amarantus partner. Amarantus intends to evaluate a smoking
cessation program, with an initial focus of getting feedback on the hemp smokable products from customers who are
actively seeking to reduce, or cease, chronic use of cigarettes and/or e-cigarettes
“We are very pleased to have come to an agreement to acquire a controlling interest in Hempori after over a year of
due diligence,” said Gerald Commissiong, President & CEO of Amarantus. “We began following Hempori right
before they opened their first retail store in December 2018, and have been thoroughly impressed with the attention
to detail and care with which Hempori manages its customers. We believe much of the value in the CBD space
resides in consumer-facing operations, and that the majority of CBD users have some medical condition for which
they are seeking wellness solutions. As such, we believe the concept of health-focused CBD wellness centers fits
squarely into the emerging health and wellness landscape. We intend to work closely with partners to optimize the
Hempori experience and expand its footprint regionally and across the United States. Amarantus will work closely
with Hempori to put Amarantus’ clinical trial and FDA-related experience to work in order to position Hempori as a
brand distribution leader in the CBD wellness solutions space for customers with medical problems.”
Under the terms of the agreement, Amarantus is issuing 25 million shares to Hempori in exchange for 51% of the
outstanding shares of Hempori, and was granted an option to acquire the remaining shares from the existing
shareholders until December 31, 2020 for additional common stock of Amarantus, or of a successor entity in the
event Amarantus is acquired prior to year-end 2020. Hempori generated over $350,000 from its 2 storefronts in fiscal
year 2019.
“We are excited to partner with Amarantus who shares a similar vision for helping customers from diverse medical
backgrounds find solutions, and capturing the data in a way that may potentially ultimately allow us to make claims
that will provide our products with a marketing advantage,” said Grant Magers, MBA, CEO of Hempori. “The time to
bring CBD to the masses is now, and we have been focused on providing a top notch customer experience that has
led to very high repeat customer rate, with the focus being on education on how to use the our products based upon
consumer feedback. This iterative process is the only way to gain a true understanding of how CBD can potentially
benefit people, allowing us to establish real-world evidence on which to base future clinical trials that show potential
benefit of our products in specific medical conditions. The initial focus on smoking cessation is due to significant
inbound demand from customers.”
Five Key Conclusions from recent Surgeon General report on Tobacco Smoking Cessation:
1. Smoking cessation is beneficial at any age. Smoking cessation improves health status and enhances quality of
life.
2. Smoking cessation reduces the risk of premature death and can add as much as a decade to life expectancy.
3. Smoking places a substantial financial burden on smokers, healthcare systems, and society. Smoking
cessation reduces this burden, including smoking attributable healthcare expenditures.
4. Smoking cessation reduces risk for many adverse health effects, including reproductive health outcomes,
cardiovascular diseases, chronic obstructive pulmonary disease, and cancer. Quitting smoking is also beneficial to
those who have been diagnosed with heart disease and chronic obstructive pulmonary disease.
5. More than three out of five U.S. adults who have ever smoked cigarettes have quit. Although a majority of
cigarette smokers make a quit attempt each year, less than one-third use cessation medications approved by the
U.S. Food and Drug Administration or behavioral counseling to support quit attempts.
NBC News recently provided a summary on this report that is available
at https://www.nbcnews.com/health/vaping/e-cigar...eral-says-
n1121361 .
About Tobacco, Smoking Cessation and E- Cigarettes
The global tobacco market is expected to grow from USD 689.4 Billion in 2018 to USD 934.5 Billion by 2026 at a
CAGR of 3.9% during the forecast period from 2019-2026. Rising use of automated techniques in manufacturing
tobacco products and online retailing is further propelling the growth are the two factors affecting the demand of the
market.
Smoking cessation (also known as quitting smoking or simply quitting) is the process of discontinuing tobacco
smoking. Tobacco smoke contains nicotine, which is addictive and can cause dependence. Nicotine withdrawal
makes the process of quitting often difficult. Cigarette smoking is the leading cause of preventable disease and
death in the United States, accounting for more than 480,000 deaths every year, or about 1 in 5 deaths, and more
than $300 billion in healthcare costs. Seventy percent of smokers would like to quit smoking, and 50 percent report
attempting to quit within the past year. Tobacco cessation significantly reduces the risk of dying from tobacco-related
diseases such as coronary heart disease, chronic obstructive pulmonary disease (COPD), and lung cancer. Due to
its link to many chronic diseases, cigarette smoking has been restricted in many public areas. In nicotine-dependent
smokers, quitting smoking can lead to symptoms of nicotine withdrawal such as nicotine cravings, anxiety, irritability,
depression, and weight gain. Professional smoking cessation support methods generally attempt to address nicotine
withdrawal symptoms to help the client break free of nicotine addiction.
E-cigarettes containing nicotine aren't considered safe for adolescents, young adults or pregnant women. Nicotine
can harm brain development in children and young adults into their early 20s and is toxic to developing fetuses.
Children and adults have also been poisoned by swallowing, breathing or absorbing e-cigarette liquid through their
skin or eyes, according to the Centers for Disease Control and Prevention. In youth and adult nonsmokers, e-
cigarette use also poses the risk of a nicotine addiction. This could lead to long-term use of e-cigarettes, the effects
of which aren't known, or to the use of traditional cigarettes. Research has shown that teen use of e-cigarettes is on
the rise and associated with increased future use of traditional cigarettes. Rarely, e-cigarettes can cause severe
harm. Defective e-cigarette batteries have caused fires and explosions, mostly while the batteries are being
charged.
About Hempori
The Hempori brand is active in the Hemp industry and has over 75 products that are sold in its own stores in Dallas,
Texas and online via Hempori.com. Hempori has developed unique proprietary products in the Hemp industry and
is actively engaged with researchers to gather data regarding the utility of its products.
About Amarantus Bioscience Holdings, Inc.
Amarantus Bioscience Holdings (AMBS) is a JLABS alumnus biotechnology company developing treatments and
diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its
subsidiaries.
Diagnostics
The Company‘s 80.01%-owned subsidiary Breakthrough Diagnostics, Inc., currently a joint venture with Todos
Medical, Ltd. has licensed intellectual property rights to the Alzheimer’s blood diagnostic LymPro Test ® from
Leipzig University that was originally developed by Dr. Thomas Arendt, as well as certain rights to multiple sclerosis
diagnostic MSPrecise™ and Parkinson’s diagnostic NuroPro. Amarantus entered into a joint venture agreement
with Todos Medical, Ltd. (OTCQB: TOMDF)to advance the diagnostic assets, and Todos has exercised its
exclusive option to acquire Amarantus’ remaining ownership in Breakthrough in exchange for approximately 49%
ownership of Todos. The transaction is expected to close in the frist half of 2020. Amarantus also owns
approximately 30% of the common shares of Avant Diagnostics, Inc, a tumor analysis company developing Theralink®, the proprietary phosphoprotein tumor analysis platform run using reverse phase protein array (RPPA)
platform.
Therapeutics
AMBS’ 50.1%-owned subsidiary Elto Pharma, Inc. has development rights to eltoprazine, a Phase 2b-ready small
molecule indicated for Parkinson's disease levodopa-induced dyskinesia, Alzheimer’s aggression and adult attention
deficit hyperactivity disorder, commonly known as ADHD. AMBS acquired Cutanogen Corporation from Lonza
Group in 2015 and currently owns 90.1% of that subsidiary. Cutanogen is preparing for pivotal studies with
Engineered Skin Substitute (ESS) for the treatment of pediatric life-threatening severe burns. ESS is a regenerative
medicine-based, autologous full-thickness skin graft technology originally developed by the Shriner’s Hospital that
can be used to treat severe burns, as well as several other catastrophic and cosmetic dermatological indications.
AMBS’ wholly-owned subsidiary, MANF Therapeutics Inc. owns key intellectual property rights and licenses from a
number of prominent universities related to the development of the therapeutic protein known as mesencephalic
astrocyte-derived neurotrophic factor (“MANF”). MANF Therapeutics is developing MANF-based products as
treatments for ophthalmological disorders such as Wolfram Syndrome, Retinitis Pigmentosa and Glaucoma, as well
as neurodegenerative diseases such as Parkinson’s disease. MANF was discovered by the Company’s Chief
Scientific Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from AMBS’ proprietary discovery
engine PhenoGuard, and believes several other neurotrophic factors remain to be discovered. MANF and ESS have
been licensed to Emerald Organic Products, Inc.
For further information please visit www.Amarantus.com, or connect with the Amarantus
on Facebook, LinkedIn, Twitter and Google+.
Amarantus Investor and Media Contact:
Gerald Commissiong
President & CEO
Office: 650-862-5391
Email: gerald@amarantus.com
Notice Regarding Forward-Looking Statements
This letter contains forward-looking statements, about the Company’s expectations, beliefs or intentions regarding,
among other things, its product development efforts, business, financial condition, results of operations, strategies or
prospects. Forward-looking statements can be identified by the use of forward-looking words such as “believe,”
“expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other
comparable words or by the fact that these statements do not relate strictly to historical or current matters. Forward-
looking statements relate to anticipated or expected events, activities, trends or results as of the date they are
made. Because forward-looking statements relate to matters that have not yet occurred, these statements are
inherently subject to risks and uncertainties that could cause actual results to differ materially from any future results
expressed or implied by the forward-looking statements. Many factors could cause actual activities or results to
differ materially from the activities and results anticipated in such forward-looking statements, including, but not
limited to, the factors summarized in the filings with the SEC. Amarantus does not undertake any obligation to
publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.
Source: Amarantus Bioscience Holdings, Inc.
Amarantus Acquires Majority Interest in CBD
Wellness Company Hempori
Strong customer retention at both stores in Dallas, TX with growing online presence
Focus on delivering wellness solutions by engaging customers to participate in clinical studies and provide
outcomes data to determine utility of branded CBD products
Order placed for hemp smokes to begin tobacco smoking cessation program
New York, NY and Dallas, TX , Jan. 30, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus
Bioscience Holdings, Inc. (OTC Pink: AMBS) (“Amarantus,” or AMBS), a biotechnology holding company pursuing
proprietary therapeutics and diagnostics through its subsidiaries, today announced that it has acquired a controlling
interest in Hempori, Inc., a CBD wellness retailer in Dallas, TXwith 2 stores and a growing physical and online
presence. Concurrent with this announcement, Hempori has placed an initial purchase order for hemp smokes from
Emerald Organic Products, Inc. (OTCPK: EMOR), an Amarantus partner. Amarantus intends to evaluate a smoking
cessation program, with an initial focus of getting feedback on the hemp smokable products from customers who are
actively seeking to reduce, or cease, chronic use of cigarettes and/or e-cigarettes
“We are very pleased to have come to an agreement to acquire a controlling interest in Hempori after over a year of
due diligence,” said Gerald Commissiong, President & CEO of Amarantus. “We began following Hempori right
before they opened their first retail store in December 2018, and have been thoroughly impressed with the attention
to detail and care with which Hempori manages its customers. We believe much of the value in the CBD space
resides in consumer-facing operations, and that the majority of CBD users have some medical condition for which
they are seeking wellness solutions. As such, we believe the concept of health-focused CBD wellness centers fits
squarely into the emerging health and wellness landscape. We intend to work closely with partners to optimize the
Hempori experience and expand its footprint regionally and across the United States. Amarantus will work closely
with Hempori to put Amarantus’ clinical trial and FDA-related experience to work in order to position Hempori as a
brand distribution leader in the CBD wellness solutions space for customers with medical problems.”
Under the terms of the agreement, Amarantus is issuing 25 million shares to Hempori in exchange for 51% of the
outstanding shares of Hempori, and was granted an option to acquire the remaining shares from the existing
shareholders until December 31, 2020 for additional common stock of Amarantus, or of a successor entity in the
event Amarantus is acquired prior to year-end 2020. Hempori generated over $350,000 from its 2 storefronts in fiscal
year 2019.
“We are excited to partner with Amarantus who shares a similar vision for helping customers from diverse medical
backgrounds find solutions, and capturing the data in a way that may potentially ultimately allow us to make claims
that will provide our products with a marketing advantage,” said Grant Magers, MBA, CEO of Hempori. “The time to
bring CBD to the masses is now, and we have been focused on providing a top notch customer experience that has
led to very high repeat customer rate, with the focus being on education on how to use the our products based upon
consumer feedback. This iterative process is the only way to gain a true understanding of how CBD can potentially
benefit people, allowing us to establish real-world evidence on which to base future clinical trials that show potential
benefit of our products in specific medical conditions. The initial focus on smoking cessation is due to significant
inbound demand from customers.”
Five Key Conclusions from recent Surgeon General report on Tobacco Smoking Cessation:
1. Smoking cessation is beneficial at any age. Smoking cessation improves health status and enhances quality of
life.
2. Smoking cessation reduces the risk of premature death and can add as much as a decade to life expectancy.
3. Smoking places a substantial financial burden on smokers, healthcare systems, and society. Smoking
cessation reduces this burden, including smoking attributable healthcare expenditures.
4. Smoking cessation reduces risk for many adverse health effects, including reproductive health outcomes,
cardiovascular diseases, chronic obstructive pulmonary disease, and cancer. Quitting smoking is also beneficial to
those who have been diagnosed with heart disease and chronic obstructive pulmonary disease.
5. More than three out of five U.S. adults who have ever smoked cigarettes have quit. Although a majority of
cigarette smokers make a quit attempt each year, less than one-third use cessation medications approved by the
U.S. Food and Drug Administration or behavioral counseling to support quit attempts.
NBC News recently provided a summary on this report that is available
at https://www.nbcnews.com/health/vaping/e-cigar...eral-says-
n1121361 .
About Tobacco, Smoking Cessation and E- Cigarettes
The global tobacco market is expected to grow from USD 689.4 Billion in 2018 to USD 934.5 Billion by 2026 at a
CAGR of 3.9% during the forecast period from 2019-2026. Rising use of automated techniques in manufacturing
tobacco products and online retailing is further propelling the growth are the two factors affecting the demand of the
market.
Smoking cessation (also known as quitting smoking or simply quitting) is the process of discontinuing tobacco
smoking. Tobacco smoke contains nicotine, which is addictive and can cause dependence. Nicotine withdrawal
makes the process of quitting often difficult. Cigarette smoking is the leading cause of preventable disease and
death in the United States, accounting for more than 480,000 deaths every year, or about 1 in 5 deaths, and more
than $300 billion in healthcare costs. Seventy percent of smokers would like to quit smoking, and 50 percent report
attempting to quit within the past year. Tobacco cessation significantly reduces the risk of dying from tobacco-related
diseases such as coronary heart disease, chronic obstructive pulmonary disease (COPD), and lung cancer. Due to
its link to many chronic diseases, cigarette smoking has been restricted in many public areas. In nicotine-dependent
smokers, quitting smoking can lead to symptoms of nicotine withdrawal such as nicotine cravings, anxiety, irritability,
depression, and weight gain. Professional smoking cessation support methods generally attempt to address nicotine
withdrawal symptoms to help the client break free of nicotine addiction.
E-cigarettes containing nicotine aren't considered safe for adolescents, young adults or pregnant women. Nicotine
can harm brain development in children and young adults into their early 20s and is toxic to developing fetuses.
Children and adults have also been poisoned by swallowing, breathing or absorbing e-cigarette liquid through their
skin or eyes, according to the Centers for Disease Control and Prevention. In youth and adult nonsmokers, e-
cigarette use also poses the risk of a nicotine addiction. This could lead to long-term use of e-cigarettes, the effects
of which aren't known, or to the use of traditional cigarettes. Research has shown that teen use of e-cigarettes is on
the rise and associated with increased future use of traditional cigarettes. Rarely, e-cigarettes can cause severe
harm. Defective e-cigarette batteries have caused fires and explosions, mostly while the batteries are being
charged.
About Hempori
The Hempori brand is active in the Hemp industry and has over 75 products that are sold in its own stores in Dallas,
Texas and online via Hempori.com. Hempori has developed unique proprietary products in the Hemp industry and
is actively engaged with researchers to gather data regarding the utility of its products.
About Amarantus Bioscience Holdings, Inc.
Amarantus Bioscience Holdings (AMBS) is a JLABS alumnus biotechnology company developing treatments and
diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its
subsidiaries.
Diagnostics
The Company‘s 80.01%-owned subsidiary Breakthrough Diagnostics, Inc., currently a joint venture with Todos
Medical, Ltd. has licensed intellectual property rights to the Alzheimer’s blood diagnostic LymPro Test ® from
Leipzig University that was originally developed by Dr. Thomas Arendt, as well as certain rights to multiple sclerosis
diagnostic MSPrecise™ and Parkinson’s diagnostic NuroPro. Amarantus entered into a joint venture agreement
with Todos Medical, Ltd. (OTCQB: TOMDF)to advance the diagnostic assets, and Todos has exercised its
exclusive option to acquire Amarantus’ remaining ownership in Breakthrough in exchange for approximately 49%
ownership of Todos. The transaction is expected to close in the frist half of 2020. Amarantus also owns
approximately 30% of the common shares of Avant Diagnostics, Inc, a tumor analysis company developing Theralink®, the proprietary phosphoprotein tumor analysis platform run using reverse phase protein array (RPPA)
platform.
Therapeutics
AMBS’ 50.1%-owned subsidiary Elto Pharma, Inc. has development rights to eltoprazine, a Phase 2b-ready small
molecule indicated for Parkinson's disease levodopa-induced dyskinesia, Alzheimer’s aggression and adult attention
deficit hyperactivity disorder, commonly known as ADHD. AMBS acquired Cutanogen Corporation from Lonza
Group in 2015 and currently owns 90.1% of that subsidiary. Cutanogen is preparing for pivotal studies with
Engineered Skin Substitute (ESS) for the treatment of pediatric life-threatening severe burns. ESS is a regenerative
medicine-based, autologous full-thickness skin graft technology originally developed by the Shriner’s Hospital that
can be used to treat severe burns, as well as several other catastrophic and cosmetic dermatological indications.
AMBS’ wholly-owned subsidiary, MANF Therapeutics Inc. owns key intellectual property rights and licenses from a
number of prominent universities related to the development of the therapeutic protein known as mesencephalic
astrocyte-derived neurotrophic factor (“MANF”). MANF Therapeutics is developing MANF-based products as
treatments for ophthalmological disorders such as Wolfram Syndrome, Retinitis Pigmentosa and Glaucoma, as well
as neurodegenerative diseases such as Parkinson’s disease. MANF was discovered by the Company’s Chief
Scientific Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from AMBS’ proprietary discovery
engine PhenoGuard, and believes several other neurotrophic factors remain to be discovered. MANF and ESS have
been licensed to Emerald Organic Products, Inc.
For further information please visit www.Amarantus.com, or connect with the Amarantus
on Facebook, LinkedIn, Twitter and Google+.
Amarantus Investor and Media Contact:
Gerald Commissiong
President & CEO
Office: 650-862-5391
Email: gerald@amarantus.com
Notice Regarding Forward-Looking Statements
This letter contains forward-looking statements, about the Company’s expectations, beliefs or intentions regarding,
among other things, its product development efforts, business, financial condition, results of operations, strategies or
prospects. Forward-looking statements can be identified by the use of forward-looking words such as “believe,”
“expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other
comparable words or by the fact that these statements do not relate strictly to historical or current matters. Forward-
looking statements relate to anticipated or expected events, activities, trends or results as of the date they are
made. Because forward-looking statements relate to matters that have not yet occurred, these statements are
inherently subject to risks and uncertainties that could cause actual results to differ materially from any future results
expressed or implied by the forward-looking statements. Many factors could cause actual activities or results to
differ materially from the activities and results anticipated in such forward-looking statements, including, but not
limited to, the factors summarized in the filings with the SEC. Amarantus does not undertake any obligation to
publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.
Source: Amarantus Bioscience Holdings, Inc.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼